Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?

Affiliations

¹ Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
² Division of Hematology Oncology in the Knight Cancer Institute, USA; Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR, USA. Electronic address: prasad@ohsu.edu.

Comment

Satish Shanbhag et al. Eur J Cancer. 2018 Nov.

. 2018 Nov:104:252-253.

doi: 10.1016/j.ejca.2018.09.021. Epub 2018 Oct 17.

¹ Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
² Division of Hematology Oncology in the Knight Cancer Institute, USA; Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR, USA. Electronic address: prasad@ohsu.edu.

No abstract available

Comment in

Letter comments on a published article in the New England Journal of Medicine.
Connors JM, Radford J. Connors JM, et al. Eur J Cancer. 2018 Nov;104:250-251. doi: 10.1016/j.ejca.2018.09.020. Epub 2018 Oct 23. Eur J Cancer. 2018. PMID: 30361101 No abstract available.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.